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Background: Although incretin therapy is clinically available in patients with type 2 diabetes undergoing
hemodialysis, no study has yet examined whether incretin therapy is capable of maintaining glycemic control in
this group of patients when switched from insulin therapy. In this study, we examined the efficacy of incretin
therapy in patients with insulin-treated type 2 diabetes undergoing hemodialysis.
Methods: Ten type 2 diabetic patients undergoing hemodialysis received daily 0.3 mg liraglutide, 50 mg
vildagliptin, and 6.25 mg alogliptin switched from insulin therapy on both the day of hemodialysis and the non-
hemodialysis day. Blood glucose level was monitored by continuous glucose monitoring. After blood glucose
control by insulin, patients were treated with three types of incretin therapy in a randomized crossover manner,
with continuous glucose monitoring performed for each treatment.
Results: During treatment with incretin therapies, severe hyperglycemia and ketosis were not observed in any
patients. Maximum blood glucose and mean blood glucose on the day of hemodialysis were significantly lower
after treatment with liraglutide compared with treatment with alogliptin (p < 0.05), but not with vildagliptin. The
standard deviation value, a marker of glucose fluctuation, on the non-hemodialysis day was significantly lower after
treatment with liraglutide compared with treatment with insulin and alogliptin (p < 0.05), but not with vildagliptin.
Furthermore, the duration of hyperglycemia was significantly shorter after treatment with liraglutide on both the
hemodialysis and non-hemodialysis days compared with treatment with alogliptin (p < 0.05), but not with
vildagliptin.
Conclusions: The data presented here suggest that patients with type 2 diabetes undergoing hemodialysis and
insulin therapy could be treated with incretin therapy in some cases.
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Diabetes is a multifactorial progressive disease accom-
panied by subsequent systematic vascular complications.
Diabetic nephropathy is one of the most critical com-
plications for diabetic patients because it can lead to se-
vere renal failure, which requires treatment with
hemodialysis (HD). Indeed, the major cause of the need
for HD is diabetic nephropathy, and this has been the
case in Japan since 1998. Controlling the blood glucose* Correspondence: tnomiyama@fukuoka-u.ac.jp
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reproduction in any medium, provided the orlevel of diabetic patients on HD is difficult, because of
frequent hypoglycemia, restriction of the use of anti-
diabetic agents, and instability of glucose, insulin, and
drug metabolites between the day of HD and the non-
HD day. However, strict glycemic control is important
for the prognosis of diabetic patients with or without
renal impairment [1]. Thus, additional effective and to-
lerable medications are urgently required for diabetic
patients with renal impairment.
In recent years, medications that mimic or enhance
incretin activity, such as glucagon-like peptide (GLP)-1
receptor agonists and dipeptidyl peptidase (DPP)-4
inhibitors, have emerged as important new treatmentsal Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Table 1 Patient characteristics at baseline
Parameter Value
n 10
Sex (male : female) 7:3
Age (years old) 62.9±4.3
Duration of diabetes (years) 25.4 ± 2.3
Duration of HD (years) 4.1±1.1
BMI (kg/m2) 23.0±1.5
Dose of insulin (U/day) 11.6±1.9
Glycated albumin (%) * 24.1 ± 1.5
S-CPR (ng/ml) 6.7 ± 1.3
spKTV 1.44 ± 0.09
Cre (mg/dl) 9.72±0.91
PTH (pg/ml) 88.0 ± 31.4
AST (U/l) 9.3 ± 1.1
ALT (U/l) 9.7 ± 1.3
gGTP (U/l) 16.9 ± 2.2
Total choresterol (mg/dl) 162.1 ± 8.1
Triglyceride (mg/dl) 120.1 ± 20.6
Blood glucose (mg/dl) 162.1 ± 8.1
Complications
Macroangiopathy (− / +) (6/4)
Neuropathy (− / +) (0/10)
Retinopathy (− / +) (0/10)
Values are means ± SEM or n. *n=9.
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glucose-dependent insulinotropic polypeptide (GIP), are
secreted after meals and act directly on pancreatic β cells
to stimulate glucose-dependent insulin secretion. GLP-1
has multiple roles in the regulation of glucose metabol-
ism, because it acts on pancreatic β cells and on other
organs, including the brain, stomach, and vasculature
[3]. However, intrinsic incretins are rapidly inactivated
by DPP-4 [4], and as a result GLP-1 receptor agonists
and DPP-4 inhibitors have been developed for the treat-
ment of type 2 diabetes.
Incretin therapy is associated with additional benefits
compared with other anti-diabetic agents. Firstly,
incretin therapy does not induce hypoglycemia, because
it controls blood glucose regulation by both insulin and
glucagon secretion depending on the blood glucose level
[5]. Additionally, incretin therapy may be able to protect
pancreatic β cell function and volume, in contrast to
sulfonylureas [6,7], and decrease blood glucose level
without weight gain [8]. Recently, DPP-4 inhibitors have
become one of the most frequently prescribed
medications for type 2 diabetes in Japan, and we have
previously reported the efficacy of a DPP-4 inhibitor,
sitagliptin, in Japanese patients with type 2 diabetes [9].
Furthermore, some incretin therapies could potentially
be used for blood glucose control in patients with type 2
diabetes who also have severe renal impairment [10].
According to the guidebook for chronic kidney disease
(CKD) in Japan [11], DPP-4 inhibitors including 50 mg
oral vildagliptin once-daily, 6.25 mg alogliptin, and the
GLP-1 receptor agonist, liraglutide 0.3 mg injected once-
daily, are available for treatment of patients with type 2
diabetes and end-stage renal disease (ESRD). However,
there are no reports comparing the efficacy and safety of
incretin therapies in diabetic patients on HD. In the
present study, we examined the efficacy and safety of
incretin therapy in patients with insulin-treated type 2




Ten Japanese insulin-treated type 2 diabetic patients
aged 34–83 years old and on HD were recruited for this
study. Patients with a history of type 1 diabetes and dia-
betic ketoacidosis, severe impairment of intrinsic insulin
secretion (serum C-peptide <2.0 ng/dL), requirement of
high dose insulin injections (≥20 U/day), severe cardiac
disease (New York Heart Association grade ≥III), or
severe liver disease were excluded.
Baseline characteristics of the 10 patients are shown in
Table 1. In this study, we measured glycated albumin
(GA) as a marker of glycemic control, because GA is a
more reliable glycemic control marker than glycatedhemoglobin in patients with renal failure [12]. Baseline
GA was 24.1 ± 1.5% and the mean duration of diabetes
was 25.4 ± 2.3 years. Duration of HD was 4.1 ± 1.1 years.
Serum-C peptide (S-CPR) was 6.7 ± 1.3 ng/mL,
suggesting that patients still had intrinsic insulin secre-
tion. The total dose of daily insulin injection was 11.6 ±
1.9 U/day. No patient had the anti-glutamic acid
dehydrogenase (GAD) antibody or history of ketoacido-
sis. During hospitalization undergoing insulin or incretin
therapy, all patients were treated with HD, thrice weekly
for 4–5 hours with a bicarbonate dialysate containing
100 mg/dL of glucose. The calculated single-pool Kt/V
[13] was 1.44 ± 0.09, suggesting sufficient efficacy of
hemodialysis.
All patients provided written informed consent to par-
ticipate. The study protocol was approved by the ethics
committees at Fukuoka University Hospital. The study
was performed in accordance with the ethical principles
stated in the Declaration of Helsinki, 1964, amended in
Edinburgh in 2000.
Methods
The present study design is shown in Figure 1. All
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Figure 2 Maximum blood glucose level (A) and minimum blood
glucose level (B). Data are presented as mean ± SEM, *p < 0.05,
n = 10, Ins; insulin, Lira; once-daily injection of 0.3 mg liraglutide,
Vilda; once-daily oral administration of 50 mg vildagliptin, Alo; once-
daily oral administration of 6.25 mg alogliptin.
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to hospital, blood glucose was controlled by insulin the-
rapy targeting a fasting blood glucose level of <130 mg/dL
and a 2 h post-prandial glucose level of <180 mg/dL with-
out hypoglycemia for 7.0 ± 0.8 days (3–13 days). After
insulin therapy, patients were treated with 0.3 mg
liraglutide, 50 mg vildagliptin, and 6.25 mg alogliptin, in a
randomized crossover design without a wash-out period.
Continuous glucose monitoring
CGM was performed during the last 2 days of insulin
therapy as a baseline evaluation, and then patients were
treated with incretin therapy. After at least 2 days of
treatment with 0.3 mg liraglutide, 50 mg vildagliptin, or
6.25 mg alogliptin, CGM was performed on both the day
of HD and the non-HD day for each incretin therapy.
CGM was performed using a CGMS System GOLD sys-
tem monitor (Medtronic MiniMed Inc., Northridge, CA,
USA). Changes in glucose were monitored by CGM for
2 successive days, and injection of liraglutide and admi-
nistration of vildagliptin or alogliptin once-daily began
at least 36 h before CGM. Based on CGM data on the
last 2 days, corresponding to the day of HD or non-HD
day, the maximum glucose level, minimum glucose level,
average and SD of 24 hours glucose, and duration of hyper-
glycemia (glucose level ≥200 mg/dL) and hypoglycemia
(glucose level <70 mg/dL) were determined and compared
the baseline on insulin with all therapies.
Statistical analysis
Summary statistics for continuous variables are presented
as mean ± standard error. One-way analysis of variance
and paired t-tests were performed to analyze differences
between incretin therapies. A value of p < 0.05 was
considered significant for all statistical tests.
Results
No severe hyperglycemia, ketosis, severe nausea, or
other adverse effects were observed in patients at any
time during incretin therapy. As shown in Figure 2A,
maximum blood glucose level was approximately
200 mg/dL for all therapies (insulin; 213.9 ± 11.5 mg/dL
(HD), 217.9 ± 15.5 mg/dL (non-HD), liraglutide; 198.2 ±
9.0 mg/dL (HD), 185.9 ± 131.1 mg/dL (non-HD),
vildagliptin; 218.8 ± 17.1 mg/dL (HD), 213.2 ± 14.1 mg/
dL (non-HD), alogliptin; 240.7 ± 18.2 mg/dL (HD),233.0 ± 20.1 mg/dL (non-HD)). For incretin therapy, the
maximum blood glucose level associated with liraglutide
was significantly lower compared with treatment with
alogliptin on both the day of HD and the non-HD day
(p < 0.05), whereas there was no significant difference
between liraglutide and vildagliptin. Conversely, there
was no significant difference in minimum blood glucose
level between the therapies (insulin; 81.8 ± 7.2 mg/dL
(HD), 88.5 ± 6.2 mg/dL (non-HD), liraglutide; 81.9 ±
5.4 mg/dL (HD), 89.6 ± 9 mg/dL (non-HD), vildagliptin;
88.1 ± 6.3 mg/dL (HD), 95.6 ± 6.0 mg/dL (non-HD),
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Figure 3 Average glucose level (A) and standard deviation (B).
Data are presented as mean ± SEM, *p < 0.05, n = 10, Ins; insulin,
Lira; once-daily injection of 0.3 mg liraglutide, Vilda; once-daily oral
administration of 50 mg vildagliptin, Alo; once-daily oral
administration of 6.25 mg alogliptin.
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(SD), a magnitude of glucose fluctuation, measured using
CGM. As shown in Figure 2A, the average blood glucose
level associated with the therapies was 120–160 mg/dL
(insulin; 134.3 ± 6.7 mg/dL (HD), 148.4 ± 10.2 mg/dL
(non-HD), liraglutide; 129.0 ± 6.2 mg/dL (HD), 135.9 ±
6.8 mg/dL (non-HD), vildagliptin; 144.3 ± 7.7 mg/dL
(HD), 149.6 ± 7.6 mg/dL (non-HD), alogliptin; 147.4 ±
7.3 mg/dL (HD), 149.7 ± 9.1 mg/dL (non-HD)).
Compared with alogliptin, liraglutide significantly de-
creased the average blood glucose level on the day of HD,
(p < 0.05). Furthermore, we compared the SD of insulin
and incretin therapies. As shown in Figure 2B, the SD of
liraglutide was lower in comparison to other treatments
(insulin; 33.4 ± 4.2 mg/dL (HD), 33.3 ± 4.7 mg/dL (non-
HD), liraglutide; 27.3 ± 1.9 mg/dL (HD), 21.5 ± 1.9 mg/dL
(non-HD), vildagliptin; 34.7 ± 6.1 mg/dL (HD), 30.2 ±
4.5 mg/dL (non-HD), alogliptin; 38.0 ± 6.5 mg/dL (HD),
32.0 ± 5.1 mg/dL (non-HD)). On the day of HD, the SD of
liraglutide was significantly lower compared with insulin
and alogliptin treatment (p < 0.05), but not with
vildagliptin (p=0.14), suggesting that liraglutide controlled
blood glucose in patients undergoing HD with smaller
glucose fluctuations.
Finally, we measured hyper- (blood glucose ≥200 mg/dL)
and hypo-glycemic (blood glucose <70 mg/dL) periods
associated with insulin and incretin therapy. As shown in
Figure 3A, liraglutide was associated with a decreased
hyperglycemic period compared with other treatments
(insulin; 40.0 ± 15.0 min/day (HD), 117.9 ± 42.4 min/day
(non-HD), liraglutide; 22.9 ± 23.9 min/day (HD), 33.3 ±
34.4 min/day (non-HD), vildagliptin; 87.1 ± 54.6 min/day
(HD), 178.7 ± 95.0 min/day (non-HD), alogliptin; 104.1 ±
38.0 min/day (HD), 77.8 ± 26.9 min/day (non-HD). Both
on the day of HD and the non-HD day, the hyperglycemic
period associated with liraglutide treatment was sig-
nificantly shorter compared with insulin and alogliptin
(p < 0.05), but not with vildagliptin. Conversely, there was
no significant difference in the hypoglycemic period be-
tween the therapies (Figure 3B, insulin; 16.3 ± 9.6 min/day
(HD), 21.7 ± 28.6 min/day (non-HD), liraglutide; 49.5 ±
70.7 min/day (HD), 23.9 ± 23.5 min/day (non-HD),
vildagliptin; 1.0 ± 1.4 min/day (HD), 1.9 ± 0.0 min/day
(non-HD), alogliptin; 6.8 ± 5.7 min/day (HD), 8.0 ±
7.5 min/day (non-HD)). The frequencies of hypoglycemic
periods were independent from the duration of
hemodialysis.
Discussion
In the present study, all 10 type 2 diabetic patients
undergoing HD were able to terminate insulin therapy
permanently, and were subsequently treated with
incretin therapy, including a once-daily injection of
0.3 mg liraglutide, once-daily oral 50 mg vildagliptin,and 6.25 mg alogliptin until at least 3 months after the
end of this study. Blood glucose data obtained from
CGM suggested that switching from insulin therapy to
incretin therapy was effective and well tolerated. After
CGM monitoring with incretin therapies, no patient
required insulin therapy, and subsequently, six patients
continued to be treated with liraglutide, two patients
with vildagliptin, and two patients with alogliptin. Their
GA 3 months later with incretin therapies was 22.9 ±
0.3%, which was lower compared with the baseline GA,
as shown in Table 1, suggesting long term tolerability of
incretin therapy in diabetic patients undergoing HD.
However, this study has some limitations, because of the
small sample size and short-term nature of the study. In
the present study, we have shown that it may be possible
to use incretin therapy in type 2 diabetes patients under-
going HD, but further study with larger sample sizes
over longer terms and including multiple regression
analysis of contributing factors to glycemic control by
incretin therapy are required to confirm the findings
here.
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Figure 4 Duration of hyperglycemia (A) and hypoglycemia (B).
Data are presented as mean ± SEM, *p < 0.05, n = 10, Ins; insulin,
Lira; once-daily injection of 0.3 mg liraglutide, Vilda; once-daily oral
administration of 50 mg vildagliptin, Alo; once-daily oral
administration of 6.25 mg alogliptin.
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HD is difficult, because of the risk of hypoglycemia. Addi-
tionally, therapeutic options for diabetic patients with
renal impairments are limited, because reduced glomeru-
lar filtration leads to an accumulation of drugs and their
metabolites [14]. Before the availability of incretin therapy,
standard treatment of diabetic patients with ESRD was
with insulin, some glinides, or α-glucosidase inhibitors.
However, incretin therapy has emerged as another option
for the treatment of diabetic patients with ESRD. Incretin
therapy may be an ideal treatment for patients with dia-
betes and ESRD, because of the low risk of hypoglycemic
events. Furthermore, as previously reported by us in an
animal model, incretin may also have a vasoprotective
effect [15,16]. Indeed, as renal impairment is one of the
risk factors that can accelerate coronary artery disease
[17]. In addition, incretin has received much attention for
its effects on fatty liver [18] and bone [19]. In the present
study, we measured liver enzymes and parathormone
(PTH) level; however, no changes were observed in these
markers after incretin therapy. The lipid lowering effect,
as we previously reported [9], was not observed in the
present study, probably because baseline lipid level was
low in the present study.
In the present study, 0.3 mg liraglutide decreased
blood glucose levels and fluctuations of blood glucose
more compared with 50 mg vildagliptin and 6.25 mg
alogliptin in diabetic patients undergoing HD. Lira-
glutide is a GLP-1 receptor agonist, which is available
for diabetic patients with renal impairment, whereas
exenatide, another GLP-1 receptor agonist, is not re-
commended for use by diabetic patients with severe
renal impairment [20]. In a previous report, the safety
and pharmacokinetics of liraglutide in subjects with
varying stages of renal impairment was examined [21].
In this report, there was no significant difference in the
pharmacokinetics and onset of adverse effects depending
on the grade of renal impairment. However, there are no
reports examining the safety of liraglutide at higher
doses and over a longer term in patients with ESRD.
In the present study, one patient was treated with
liraglutide for over 9 months without adverse effects.
However, further studies are required to confirm the
safety and efficacy of liraglutide in diabetic patients
undergoing HD. Theoretically, incretin therapy should
not cause hypoglycemia. However, we observed hypogly-
cemic periods, and 0.3 mg liraglutide was associated
with the highest frequency of hypoglycemia (Figure 4B).
These data suggest that both hyperglycemia and
hypoglycemia should be monitored when treating dia-
betic patients undergoing HD with incretin therapy. In
the present study, the lowest hypoglycemic period,
which was not significantly different from other thera-
pies, was observed with vildagliptin.Similar to our present study, other groups have previ-
ously demonstrated the efficacy and tolerability of the
DPP-4 inhibitor, vildagliptin, in type 2 diabetic patients
undergoing HD [22,23]. Kume et al. treated drug naïve
type 2 diabetic patients undergoing HD with 50 mg
vildagliptin once-daily for 24 weeks, and observed a sig-
nificant reduction in postprandial glucose and GA from
the baseline data [20]. Ito et al. treated type 2 diabetic
patients undergoing HD with once-daily 50 mg or 100 mg
vildagliptin for 24 weeks, and observed a significant re-
duction in HbA1c, GA, and postprandial glycemia [23].
Additionally, the efficacy of alogliptin in type 2 diabetic
patients undergoing HD was also reported by another
group [24]. Although these reports suggest efficacy and
safety of DPP-4 inhibitors for the treatment of patients
with type 2 diabetes undergoing HD, caution should still
be exercised when treating patients undergoing HD.
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liptin are excreted via the kidney [25], there is a risk that
these compounds may accumulate during long-term use.
Very recently, linagliptin, which is primarily excreted via
bile acid, has become available [26]. According to CKD
guidelines [11], linagliptin does not require dose reduction
even in patients with ESRD, because of the stable pharma-
cokinetics of this compound in such patients. Unfortu-
nately, we were not able to include linagliptin in the
present study. However, it could potentially become a
treatment option for diabetic patients undergoing HD in
the future.
As described above, several reports have examined the
efficacy of incretin therapy in type 2 diabetic patients
undergoing HD. However, there have been no reports
demonstrating a switch from insulin to incretin thera-
py in the treatment of diabetic patients undergoing HD.
In the present study, we recruited patients who had
S-CPR ≥2.0 ng/dL. Because the glucose lowering effect
of incretin therapy depends on intrinsic insulin secre-
tion, S-CPR needs to be high for incretin therapy to be
effective. Baseline S-CPR of patients who completed the
current study was 6.7 ± 1.3 ng/mL (2.25-16.3 ng/mL),
suggesting that 2.0 ng/mL might be the borderline S-
CPR concentration with which insulin therapy could be
switched to incretin therapy in type 2 diabetic patients
undergoing HD. In addition, we recruited patients who
did not require insulin injections of >20 U/day to ac-
hieve good glycemic control, based on our preliminary
experience. In the present study, baseline insulin injec-
tion dose was 11.6 ± 1.9 U/day (4–19 U/day).
Furthermore, this is the first report demonstrating
CGM of incretin therapy in type 2 diabetic patients
undergoing HD. CGM can monitor blood glucose levels
for 24 hours, and detect the average and fluctuation
range of blood glucose. Because incretin therapy can de-
crease not only the average blood glucose, but also
fluctuations of glucose level, CGM is ideal for the evalu-
ation of glycemic control in incretin therapy [27]. In the
present study, incretin therapy, especially liraglutide,
controlled both the average and fluctuation of glucose
level in type 2 diabetic patients undergoing HD.
Conclusions
This study has shown that it is possible that insulin-
treated type 2 diabetic patients undergoing HD might be
able to switch from insulin to incretin therapy, if they have
a serum C-peptide ≥2.0 ng/dL and an insulin injection
dose <20 U/day. However, further studies with larger pa-
tient groups and over longer study periods are required to
confirm the findings of the present study.
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